Skip to content
DataLookout
Menu

Epilepsy clinical trials

Get alerts when Epilepsy trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05

What changed in the last 30 days

47 trials changed in the last 30 days: 2 stopped, 26 with notable changes, 19 with minor changes only.

  1. Notable: UX-GIP001 · Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy Recruitment opened Shanghai UniXell Biotechnology Co., LtdPhase 1 NCT07572812
  2. Minor: OPERA · Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting Trial completed Jazz PharmaceuticalsNot specified NCT05772429
  3. Notable: HOBSCOTCH-YOUTH and Young Adults Primary completion pushed from Sep 1, 2028 to May 1, 2029 Dartmouth-Hitchcock Medical CenterNot applicable NCT07735715
  4. Minor: X-ACKT · XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures Trial sites expanded: 138 → 141 locations Xenon Pharmaceuticals Inc.Phase 3 NCT05667142
  5. Minor: BLUELIGHTVNS · Blue Light on Vagus Nerve Stimulation · Refractory Epilepsy Study completion pushed from Apr 2026 to Dec 2026 Cliniques universitaires Saint-Luc- Université Catholique de LouvainNot applicable NCT06304389
  6. Notable: CoSMos · Combined CM and STN Stimulation for Motor Epilepsy Recruitment opened Boston Scientific CorporationNot applicable NCT07458217
  7. Minor: SLEEP-TIES · Lily's Grace Temporal Interference Start date pushed from Oct 2026 to Nov 2026 University of Wisconsin, MadisonNot applicable NCT07520955
  8. Notable: ARGUS · EPX-100 (Clemizole Hydrochloride) · Dravet Syndrome Primary endpoint(s) modified EpygenixPhase 3 NCT04462770
  9. Minor: TSC-STEPS · Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Enrollment closed, study ongoing Darcy KruegerPhase 2 NCT05104983
  10. Notable: HIFU for MRGE · High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus · Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years Primary endpoint(s) modified Oregon Health and Science UniversityNot applicable NCT07803692
  11. Notable: Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG) Primary and study completion pushed from Aug 3, 2026 to Dec 31, 2027 CREmedicalNot specified NCT05944692
  12. Minor: SPN-817 Open-Label Extension Study · Focal Onset Seizures Trial status changed: Recruiting → Enrolling by Invitation Supernus Pharmaceuticals, Inc.Phase 2 NCT07141329
  13. Minor: LP352 in Children and · Dravet Syndrome (DS) Enrollment increased: 96 → 108 participants Longboard PharmaceuticalsPhase 3 NCT06660394
  14. Minor: BTSEE · Biomarker Targeted Stimulation for Epileptiform Events Study completion pushed from Feb 14, 2030 to Nov 1, 2030 Cadence NeuroscienceNot applicable NCT06424977
  15. Minor: Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Primary and study completion pushed from Oct 31, 2026 to Mar 29, 2027 UCB Biopharma SRLPhase 3 NCT05077904
  16. Minor: FOCUS 1 · RAP-219 · Focal Seizures FOCUS-1 Trial sites expanded: 15 → 18 locations Rapport Therapeutics Inc.Phase 3 NCT07563881
  17. Notable: ENDEAVOR · ETX101 in Infants and · SCN1A-Positive Dravet Syndrome Enrollment increased: 47 → 113 participants Encoded TherapeuticsPhase 1/2 NCT05419492
  18. Notable: RaRE-TS · Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex Primary and study completion pushed from Jun 2027 to Sep 2029 Katarzyna KotulskaPhase 3 NCT05534672
  19. Minor: DETECT LTFU · Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up Trial sites expanded: 18 → 21 locations Epiminder America, Inc.Not specified NCT07110454
  20. Notable: Oxygen Toxicity: Mechanisms in Humans Recruitment resumed after suspension Duke UniversityNot applicable NCT05761756
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-03 NCT07911774 Edge AI Neurostimulation Controllers Versus Continuous Therapy for Drug-Resistant Focal… Lahore Medical and Dental College new
2026-10-29 NCT07904039 Characterisation of Laryngeal Evoked Potentials Induced by Vagus Nerve Stimulation in… Université Catholique de Louvain new
2026-10-08 NCT07865546 Advanced Space-time Resolved Techniques for Functional Neuroimaging at 7 Tesla MRI Imago 7 Fondazione di Ricerca onlus new
2026-10-02 NCT07854093 Impact of Epilepsy on Motor Function, Fatigue, and Quality of Life Borna Farhoomand new
2026-09-23 NCT07835594 Studying Heart Rhythms With a Wearable Sensor to Detect and Predict Seizures in People… Acibadem University new
2026-09-18 NCT07828496 Cognitive Rehabilitation Using Neurofeedback With Brain-computer Interface KK Women's and Children's Hospital new
2026-09-16 NCT07821697 Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG… Adraxe Corp. new Early Phase 1
2026-08-28 NCT07793396 Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures King Edward Medical University new
2026-08-27 NCT07790224 Multi-Parameter Temporal Interference Stimulation in Patients With Epilepsy Undergoing… Beijing Sanbo Brain Hospital new
2026-08-20 NCT07775976 Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using… Peerbridge Health, Inc new

Active trials by phase

Early Phase 1
15
Phase 1
13
Phase 1/2
19
Phase 2
32
Phase 2/3
9
Phase 3
44
Phase 4
21
Not charted: 469 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Epilepsy trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials